Paper Details

Paper Title

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.

Paper Journal Title

Blood

Paper Citation Count

Paper Publication Year

2023

Bio Mention

Mesh Descriptor

Author Name	Affiliation
Christopher J Gibson	Harvard Medical School
Christopher J Gibson	Dana-Farber Cancer Institute
David T Scadden	Center for Regenerative Medicine, Massachusetts General Hospital
David T Scadden
David T Scadden	Harvard University
David T Scadden	Harvard Stem Cell Institute, Harvard University
David T Scadden	Harvard Medical School
Kimberly Stegmaier	Harvard Medical School
Kimberly Stegmaier	Broad Institute of MIT and Harvard
Kimberly Stegmaier	Dana-Farber Cancer Institute
Kimberly Stegmaier	Harvard Medical School
Kimberly Stegmaier	Broad Institute of MIT and Harvard
Kimberly Stegmaier	Dana-Farber Cancer Institute
Robert Coleman Lindsley	Harvard Medical School
Robert Coleman Lindsley	Broad Institute of MIT and Harvard
Robert Coleman Lindsley	Dana-Farber Cancer Institute
Benjamin L Ebert	Harvard Medical School
Benjamin L Ebert	Broad Institute of MIT and Harvard
Benjamin L Ebert	Dana-Farber Cancer Institute
Benjamin L Ebert	Howard Hughes Medical Institute

Column Actions